<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172507</url>
  </required_header>
  <id_info>
    <org_study_id>NL58806.091.16</org_study_id>
    <nct_id>NCT03172507</nct_id>
  </id_info>
  <brief_title>The Role of Stem Cells on Immune Cells in the Development of Cardiovascular Diseases</brief_title>
  <acronym>ATHEROSTEM</acronym>
  <official_title>Phenotypic and Epigenetic &quot;Trained Immunity&quot; Characteristics of Hematopoietic Stem and Progenitor Cells in Patients With Established Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canisius-Wilhelmina Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An observational pilot proof-of-principle study. 15 patients with significant coronary artery&#xD;
      disease and 15 matched controls. To investigate whether long-term activation of the innate&#xD;
      immune system, named 'trained innate immunity', occurs at the level of the bone marrow&#xD;
      progenitor cells in patients with significant coronary artery disease and whether this&#xD;
      correlates with the proinflammatory phenotype of monocytes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 20, 2017</start_date>
  <completion_date type="Actual">October 1, 2018</completion_date>
  <primary_completion_date type="Actual">August 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Weeks</target_duration>
  <primary_outcome>
    <measure>Phenotypical characteristics of HSPC's</measure>
    <time_frame>Study day 2 for patients</time_frame>
    <description>Phenotypical characteristics of HSPC's populations of patients with and without significant coronary artery disease by flowcytometry in percentages.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine response of circulating monocytes</measure>
    <time_frame>Study day 2 for patients</time_frame>
    <description>Cytokine response of monocytes of patients with and without significant coronary artery disease after 24 hour stimulation with several stimuli measured in cytokine levels.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">27</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Atherosclerosis group</arm_group_label>
    <description>Patients with significant coronary artery disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Healthy controls without confirmed coronary artery disease.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, plasma and bone marrow&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study will include 15 patients with significant coronary artery disease and 15&#xD;
        patients without significant coronary artery disease. Patients who have been presented to&#xD;
        the cardiology departments of the CWZ hospital or Radboud University Medical Centre and&#xD;
        have undergone CCTA in the past two years are eligible to participate if they meet the in-&#xD;
        and exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 and ≤75 years&#xD;
&#xD;
          -  With or without significant coronary artery disease on CCTA&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic infections&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Medical history of any disease associated with immune deficiency&#xD;
&#xD;
          -  Clinically significant infections within 3 months prior to study entry&#xD;
&#xD;
          -  Recent hospital admission or surgery with general anaesthesia&#xD;
&#xD;
          -  Known chronic kidney or liver disease&#xD;
&#xD;
          -  Previous vaccination within 3 months prior to study entry&#xD;
&#xD;
          -  Inability to personally provide written informed consent&#xD;
&#xD;
          -  Inability to undergo PET-CT scanning&#xD;
&#xD;
          -  Chronic use of anti-inflammatory drugs such as NSAIDs&#xD;
&#xD;
          -  History of haematological malignant disease&#xD;
&#xD;
          -  Documented bleeding diathesis or thrombocytopenia&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels P. Riksen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of cardiology, CWZ</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of cardiology, Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>May 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematopoietic Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

